ATE370130T1 - Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten - Google Patents

Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten

Info

Publication number
ATE370130T1
ATE370130T1 AT01994985T AT01994985T ATE370130T1 AT E370130 T1 ATE370130 T1 AT E370130T1 AT 01994985 T AT01994985 T AT 01994985T AT 01994985 T AT01994985 T AT 01994985T AT E370130 T1 ATE370130 T1 AT E370130T1
Authority
AT
Austria
Prior art keywords
agent
compounds
compound
formula
diseases
Prior art date
Application number
AT01994985T
Other languages
English (en)
Inventor
Hisao Tajima
Yoshisuke Nakayama
Daikichi Fukushima
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE370130T1 publication Critical patent/ATE370130T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01994985T 2000-12-25 2001-12-21 Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten ATE370130T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000392723 2000-12-25

Publications (1)

Publication Number Publication Date
ATE370130T1 true ATE370130T1 (de) 2007-09-15

Family

ID=18858667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994985T ATE370130T1 (de) 2000-12-25 2001-12-21 Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten

Country Status (23)

Country Link
US (2) US7220864B2 (de)
EP (2) EP1354879B1 (de)
JP (1) JP3491635B2 (de)
KR (2) KR100635315B1 (de)
CN (1) CN100357280C (de)
AT (1) ATE370130T1 (de)
BR (1) BR0116526A (de)
CA (1) CA2432211C (de)
CZ (1) CZ20031772A3 (de)
DE (1) DE60130031T2 (de)
DK (1) DK1354879T3 (de)
ES (1) ES2291378T3 (de)
HU (1) HUP0303636A3 (de)
IL (2) IL156505A0 (de)
MX (1) MXPA03005763A (de)
NO (1) NO327132B1 (de)
NZ (1) NZ526687A (de)
PL (1) PL207798B1 (de)
PT (1) PT1354879E (de)
RU (1) RU2268262C2 (de)
TW (1) TWI235748B (de)
WO (1) WO2002051820A1 (de)
ZA (1) ZA200304913B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
AU2003263814A1 (en) * 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308354A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) * 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
WO2005103017A1 (ja) * 2004-04-20 2005-11-03 Ono Pharmaceutical Co., Ltd. 難溶性薬物の比表面積増大方法
AU2006311523A1 (en) * 2005-11-07 2007-05-18 Irm Llc Oxazole and thiazole PPAR modulator
JP5718233B2 (ja) 2008-10-20 2015-05-13 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体(tshr)の低分子量アゴニスト
JP5965387B2 (ja) 2010-04-08 2016-08-03 アメリカ合衆国 Tsh受容体用のインバースアゴニストおよびニュートラルアンタゴニスト
WO2012027482A2 (en) * 2010-08-24 2012-03-01 Georgetown University Compounds, compositions and methods related to ppar antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers

Also Published As

Publication number Publication date
US20060287304A1 (en) 2006-12-21
BR0116526A (pt) 2004-07-06
RU2268262C2 (ru) 2006-01-20
PL363583A1 (en) 2004-11-29
DE60130031D1 (de) 2007-09-27
KR100718906B1 (ko) 2007-05-18
EP1354879A4 (de) 2004-09-22
PT1354879E (pt) 2007-10-29
CN1489582A (zh) 2004-04-14
EP1354879A1 (de) 2003-10-22
EP1726586A1 (de) 2006-11-29
CA2432211A1 (en) 2002-07-04
US20040138213A1 (en) 2004-07-15
KR100635315B1 (ko) 2006-10-18
CZ20031772A3 (cs) 2003-11-12
KR20030064871A (ko) 2003-08-02
ZA200304913B (en) 2004-01-22
DK1354879T3 (da) 2007-12-17
NO327132B1 (no) 2009-04-27
HUP0303636A2 (hu) 2004-03-01
TWI235748B (en) 2005-07-11
NZ526687A (en) 2004-08-27
JPWO2002051820A1 (ja) 2004-04-22
JP3491635B2 (ja) 2004-01-26
CN100357280C (zh) 2007-12-26
KR20060083436A (ko) 2006-07-20
CA2432211C (en) 2010-07-13
NO20032895D0 (no) 2003-06-23
IL156505A0 (en) 2004-01-04
DE60130031T2 (de) 2008-05-15
IL156505A (en) 2009-09-22
MXPA03005763A (es) 2004-05-03
EP1354879B1 (de) 2007-08-15
WO2002051820A1 (en) 2002-07-04
ES2291378T3 (es) 2008-03-01
HUP0303636A3 (en) 2006-02-28
PL207798B1 (pl) 2011-02-28
US7220864B2 (en) 2007-05-22
NO20032895L (no) 2003-08-25

Similar Documents

Publication Publication Date Title
ATE451346T1 (de) Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE60130031D1 (de) Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
WO2001096311A3 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
EP1122255A4 (de) Carbonsäurederivate und medikamente die diese als aktiven inhaltsstoff enthalten
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
BR0016064A (pt) Compostos heterocìclicos e seus sais e uso medicinal dos mesmos
TNSN04164A1 (fr) Inhibiteurs de acc.
CA2476800A1 (en) Crystals of glucopyranosyloxybenzyl benzene derivative
RU2007101492A (ru) Способ и композиция для лечения ожирения, инсулинзависимых заболеваний и гиперхолестеринемии
CH635096A5 (fr) Chlorhydrate dihydrate de 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine et medicament le contenant.
EP1108713A4 (de) Carbonsäurederivate und sie als aktiven bestandteil enthaltende medikamente
JPH01299289A (ja) 血糖降下剤としてのチアゾリジンジオン誘導体
WO2009087285A4 (fr) 5,6-diaryles pyridines substitues en position 2 et 3, leur preparation et leur application en therapeutique
CA2344144A1 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
NO963186D0 (no) Neurobeskyttende kromanforbindelser
DK0674515T3 (da) Anvendelse af carbostyrilderivater til fremstilling af et medikament til inhibering af interleukin-8
ATE15181T1 (de) (z)-1-aryl-2-aminomethyl-cyclopropan-carboxylat , ihre herstellung und ihre verwendung als arzneimittel fuer die behandlung von verschiedenen schmerzen.
BRPI0408325A (pt) compostos derivados de imino éter e medicamentos contendo os compostos como o ingrediente ativo
WO2003042194A1 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
CA2365085A1 (en) Therapeutic agents for diabetes
ATE185803T1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
ATE252563T1 (de) Vorsorge-/heilmittel fur die komplikationen von diabetes
Gunalan et al. Insights of Novel Anti-Inflammatory Drugs Targeting Phosphodiesterase and Their Characterization: An In-Silico and In-Vitro Approach
JPH03193730A (ja) 治療剤
KR870008874A (ko) 4-(2-피리미디닐)-1-피페라지닐 헤테로사이클릭 카보닐유도체 및 그의 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1354879

Country of ref document: EP